Document Type

Article

Publication Title

Cureus

Abstract

Computed tomography (CT), magnetic resonance imaging (MRI), and bone scintigraphy are utilized to diagnose and stage prostate cancer. There is a growing interest in the utilization of prostate-specific membrane antigen-positive emission tomography (PSMA PET) scans for the diagnosis and monitoring of prostate cancer. Here, we present a case of biopsy-proven prostate cancer with solitary focal splenic uptake on PSMA PET initially concerning for splenic metastasis. Further imaging with MRI indicated a benign splenic etiology in this case. The patient underwent radiation therapy (RT) and initiated two years of androgen deprivation therapy (ADT) for high-risk localized prostate adenocarcinoma. The patient’s prostate-specific antigen (PSA) level decreased from a peak of 93.6 to 0.165 following treatment. Repeat PSMA PET scan three months post-radiation demonstrated no change in the splenic lesion despite decreased PSA. This case suggests that benign splenic lesions can demonstrate PSMA uptake on imaging and should be considered in cases of PSMA focal uptake in the spleen. This is significant because the presence of true metastases on PSMA PET scan significantly changes treatment recommendations for the patient. Further evaluation of benign findings that demonstrate PSMA avidity and appropriate follow-up testing for confirmation is necessary to avoid harmful overtreatment of patients.

DOI

10.7759/cureus.109214

Publication Date

5-19-2026

Keywords

mri, prostate cancer, psa, psma pet, radiation therapy, splenic metastasis

ISSN

2168-8184

Download

Share

COinS